A study evaluating intestinal FDG accumulation on 18F-FDG-PET/MRI in patients taking imeglimin or metformi
Not Applicable
Recruiting
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000046509
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients with the following contraindications to Buscopan (butyl scopolamine bromide) patients with hemorrhagic colitis patients with angle-closure glaucoma patients with dysuria due to prostatic hypertrophy patients with severe heart disease patients with paralytic ileus patients with a history of allergy to this drug 2. patients with possible intestinal perforation or obstruction 3. patients with metalic device in the body that cannot be tested by PET/MRE 4. other patients who are judged unsuitable for this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FDG excretion into the intestinal tract by 18F-FDG-PET/MRE
- Secondary Outcome Measures
Name Time Method